| Molecular Weight: | 438.52 |
| Formula: | C25H30N2O5 |
| Purity: | ≥98% |
| CAS#: | n/a |
| Solubility: | DMSO up to 50 mM |
| Chemical Name: | cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate |
| Storage: | Powder:4oC 1 year. DMSO:4oC3 month;-20oC 1 year. |
Biological Activity:
FLI-06 is a novel potent and selective small molecule intercepting Notch signaling and the early secretory pathway (EC50~2.3 µM), identified by using automated microscopy to monitor the trafficking and processing of a ligand-independent Notch-GFP fusion reporter. FLI-06 can induce accumulation of the reporter at the plasma membrane by interfering with transport in the secretory pathway. It can also disrupt the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibited general secretion at a step before exit from the endoplasmic reticulum (ER), which was accompanied by a tubule-to-sheet morphological transition of the ER, rendering FLI-06 the first small molecule acting at such an early stage in secretory traffic. FLI-06 is a very useful chemical probe to study the inhibition of membrane traffic at pre- ER-exit site (ERES) stages without fusion of ER-Golgi.
How to Use:
- In vitro: FLI-06 was used at 10 µM final concentration in vitro and in cellular assays.
- In vivo:FLI-06 was applied at 50 μM in E3 embryo medium to zebrafish embryos with chorions torn but not completely removed from the sphere stage until the stage of analysis.
Reference:
- 1. Krämer A, et al. Small molecules intercept Notch signaling and the early secretory pathway. (2013) Nat Chem Biol. 9(11):731-8.
FLI-06_spec.pdf- FLI-06_MSDS.pdf
Products are for research use only. Not for human use. |
